Immunome (NASDAQ:IMNM) Hits New 12-Month High – What’s Next?

Shares of Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $25.55 and last traded at $25.7450, with a volume of 2059550 shares changing hands. The stock had previously closed at $24.87.

Analyst Upgrades and Downgrades

IMNM has been the topic of several research analyst reports. Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a research report on Thursday, January 15th. Lake Street Capital increased their price target on shares of Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Guggenheim raised their price objective on shares of Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Leerink Partners set a $40.00 price objective on shares of Immunome in a research report on Monday, December 15th. Finally, Evercore ISI increased their target price on shares of Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Immunome Stock Up 3.8%

The company has a market cap of $2.37 billion, a P/E ratio of -8.75 and a beta of 2.22. The firm’s 50-day moving average price is $20.23 and its 200-day moving average price is $14.72.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Insider Buying and Selling at Immunome

In related news, Director Isaac Barchas sold 383,200 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the sale, the director owned 2,031,181 shares of the company’s stock, valued at approximately $44,157,874.94. This represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Clay B. Siegall bought 46,511 shares of the stock in a transaction on Thursday, December 18th. The stock was purchased at an average price of $21.50 per share, for a total transaction of $999,986.50. Following the completion of the purchase, the chief executive officer directly owned 853,247 shares in the company, valued at approximately $18,344,810.50. This represents a 5.77% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 68,518 shares of company stock valued at $1,453,958 in the last quarter. 7.69% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Stoneridge Investment Partners LLC lifted its position in Immunome by 5.4% in the 3rd quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock worth $143,000 after buying an additional 620 shares during the last quarter. ANTIPODES PARTNERS Ltd grew its position in Immunome by 6.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock valued at $128,000 after acquiring an additional 631 shares during the last quarter. Creative Planning raised its stake in shares of Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after acquiring an additional 710 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Immunome by 6.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock worth $172,000 after acquiring an additional 1,188 shares during the last quarter. Finally, Main Management ETF Advisors LLC lifted its holdings in shares of Immunome by 1.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 76,944 shares of the company’s stock worth $716,000 after acquiring an additional 1,248 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.